Uncategorized

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection)

Mallinckrodt plc announced the publication of two journal manuscripts reinforcing the clinical and economic evidence supporting the efficacy, safety profile, continued use, and cost-effectiveness of Acthar Gel for appropriate patients across a range of FDA-approved autoimmune and inflammatory disease indications.

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection) Read More »

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer

NanOlogy LLC announced that initial safety and clinical outcomes from a Phase 2 clinical trial of intratumoral large surface area microparticle paclitaxel in locally advanced pancreatic cancer were published online ahead of print in Pancreas and two posters were presented at the ninth AACR Special Conference on Pancreatic Cancer in Boston reporting downstaging and immune

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer Read More »

Scroll to Top